Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models

The purpose of this collection is to provide a forum to integrate pre-clinical and clinical investigations regarding the long-term consequences of adolescent exposure to drugs of abuse. Adolescence is characterized by numerous behavioral and biological changes, including substantial neurodevelopment...

Full description

Saved in:
Bibliographic Details
Superior document:Frontiers Research Topics
:
Year of Publication:2018
Language:English
Series:Frontiers Research Topics
Physical Description:1 electronic resource (201 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993544398604498
ctrlnum (CKB)4920000000094249
(oapen)https://directory.doabooks.org/handle/20.500.12854/51977
(EXLCZ)994920000000094249
collection bib_alma
record_format marc
spelling Mary M. Torregrossa auth
Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models
Long-Term Consequences of Adolescent Drug Use
Frontiers Media SA 2018
1 electronic resource (201 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Frontiers Research Topics
The purpose of this collection is to provide a forum to integrate pre-clinical and clinical investigations regarding the long-term consequences of adolescent exposure to drugs of abuse. Adolescence is characterized by numerous behavioral and biological changes, including substantial neurodevelopment. Behaviorally, adolescents are more likely to engage in risky activities and make impulsive decisions. As such, the majority of substance use begins in adolescence, and an earlier age of onset of use (<15 yr) is strongly associated with the risk for developing a substance use disorder later in life. Furthermore, adolescent drug use may negatively impact ongoing neurological development, which could lead to long-term cognitive and emotional deficits. A large number of clinical studies have investigated both the acute and long-term effects of adolescent drug use on functional outcomes. However, the clinical literature contains many conflicting findings, and is often hampered by the inability to know if functional differences existed prior to drug use. Moreover, in human populations it is often very difficult to control for the numerous types of drugs, doses, and combinations used, not to mention the many other environmental factors that may influence adult behavior. Therefore, an increase in the number of carefully controlled studies using relevant animal models has the potential to clarify which adolescent experiences, particularly what drugs used when, have long-term negative consequences. Despite the advantages of animal model systems in clarifying these issues, the majority of pre-clinical addiction research over the past 50+ years has been conducted in adult animals. Moreover, few addiction-related studies have investigated the long-term neurocognitive consequences of drug exposure at any age. In the past 10 years of so, however, the field of adolescent drug abuse research has burgeoned. To date, the majority of this research has focused on adolescent alcohol exposure using a variety of animal models. The results have given the field important insight into why adolescents are more likely to drink alcohol to excess relative to adults, and the danger of adolescent alcohol use (e.g., in leading to a persistence of excessive drinking in adulthood). More recently, research regarding the effects of adolescent exposure to other drugs of abuse, including nicotine, cocaine, and cannabinoids has expanded. Therefore, we are at unique point in time, when emerging results from carefully controlled pre-clinical studies can inform the sometimes confusing clinical literature. In addition, we expect an influx of prospective clinical studies in response to a cross-institute initiative at NIH, known as the ABCD grant. Several institutes are enrolling children prior to adolescence (and the initiation of drug use), in order to control for pre-existing neurobiological and neurobehavioral differences and to monitor the age of initiation and amount of drug used more carefully than is possible using retrospective designs.
English
alcohol
stress
nicotine
cocaine
ketamine
methamphetamine
cannabinoid
prefrontal cortex
juvenile
sex differences
2-88945-530-0
Jacqueline M. Barker auth
Shannon L. Gourley auth
language English
format eBook
author Mary M. Torregrossa
spellingShingle Mary M. Torregrossa
Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models
Frontiers Research Topics
author_facet Mary M. Torregrossa
Jacqueline M. Barker
Shannon L. Gourley
author_variant m m t mmt
author2 Jacqueline M. Barker
Shannon L. Gourley
author2_variant j m b jmb
s l g slg
author_sort Mary M. Torregrossa
title Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models
title_full Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models
title_fullStr Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models
title_full_unstemmed Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models
title_auth Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models
title_alt Long-Term Consequences of Adolescent Drug Use
title_new Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models
title_sort long-term consequences of adolescent drug use: evidence from pre-clinical and clinical models
series Frontiers Research Topics
series2 Frontiers Research Topics
publisher Frontiers Media SA
publishDate 2018
physical 1 electronic resource (201 p.)
isbn 2-88945-530-0
illustrated Not Illustrated
work_keys_str_mv AT marymtorregrossa longtermconsequencesofadolescentdruguseevidencefrompreclinicalandclinicalmodels
AT jacquelinembarker longtermconsequencesofadolescentdruguseevidencefrompreclinicalandclinicalmodels
AT shannonlgourley longtermconsequencesofadolescentdruguseevidencefrompreclinicalandclinicalmodels
AT marymtorregrossa longtermconsequencesofadolescentdruguse
AT jacquelinembarker longtermconsequencesofadolescentdruguse
AT shannonlgourley longtermconsequencesofadolescentdruguse
status_str n
ids_txt_mv (CKB)4920000000094249
(oapen)https://directory.doabooks.org/handle/20.500.12854/51977
(EXLCZ)994920000000094249
carrierType_str_mv cr
hierarchy_parent_title Frontiers Research Topics
is_hierarchy_title Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models
container_title Frontiers Research Topics
author2_original_writing_str_mv noLinkedField
noLinkedField
_version_ 1787548761604489216
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04301nam-a2200421z--4500</leader><controlfield tag="001">993544398604498</controlfield><controlfield tag="005">20231214133604.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2018 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4920000000094249</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/51977</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994920000000094249</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Mary M. Torregrossa</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Long-Term Consequences of Adolescent Drug Use: Evidence from Pre-Clinical and Clinical Models</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Long-Term Consequences of Adolescent Drug Use</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (201 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The purpose of this collection is to provide a forum to integrate pre-clinical and clinical investigations regarding the long-term consequences of adolescent exposure to drugs of abuse. Adolescence is characterized by numerous behavioral and biological changes, including substantial neurodevelopment. Behaviorally, adolescents are more likely to engage in risky activities and make impulsive decisions. As such, the majority of substance use begins in adolescence, and an earlier age of onset of use (&lt;15 yr) is strongly associated with the risk for developing a substance use disorder later in life. Furthermore, adolescent drug use may negatively impact ongoing neurological development, which could lead to long-term cognitive and emotional deficits. A large number of clinical studies have investigated both the acute and long-term effects of adolescent drug use on functional outcomes. However, the clinical literature contains many conflicting findings, and is often hampered by the inability to know if functional differences existed prior to drug use. Moreover, in human populations it is often very difficult to control for the numerous types of drugs, doses, and combinations used, not to mention the many other environmental factors that may influence adult behavior. Therefore, an increase in the number of carefully controlled studies using relevant animal models has the potential to clarify which adolescent experiences, particularly what drugs used when, have long-term negative consequences. Despite the advantages of animal model systems in clarifying these issues, the majority of pre-clinical addiction research over the past 50+ years has been conducted in adult animals. Moreover, few addiction-related studies have investigated the long-term neurocognitive consequences of drug exposure at any age. In the past 10 years of so, however, the field of adolescent drug abuse research has burgeoned. To date, the majority of this research has focused on adolescent alcohol exposure using a variety of animal models. The results have given the field important insight into why adolescents are more likely to drink alcohol to excess relative to adults, and the danger of adolescent alcohol use (e.g., in leading to a persistence of excessive drinking in adulthood). More recently, research regarding the effects of adolescent exposure to other drugs of abuse, including nicotine, cocaine, and cannabinoids has expanded. Therefore, we are at unique point in time, when emerging results from carefully controlled pre-clinical studies can inform the sometimes confusing clinical literature. In addition, we expect an influx of prospective clinical studies in response to a cross-institute initiative at NIH, known as the ABCD grant. Several institutes are enrolling children prior to adolescence (and the initiation of drug use), in order to control for pre-existing neurobiological and neurobehavioral differences and to monitor the age of initiation and amount of drug used more carefully than is possible using retrospective designs.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">alcohol</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stress</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nicotine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cocaine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ketamine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">methamphetamine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cannabinoid</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prefrontal cortex</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">juvenile</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sex differences</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88945-530-0</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jacqueline M. Barker</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shannon L. Gourley</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:58:37 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2019-11-10 04:18:40 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5337582150004498&amp;Force_direct=true</subfield><subfield code="Z">5337582150004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337582150004498</subfield></datafield></record></collection>